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Abstract
Cathelicidins are multifunctional cationic host-defence peptides (CHDP; also known as antimicrobial peptides) and an
important component of innate host defence against infection. In addition to microbicidal potential, these peptides have
properties with the capacity to modulate inflammation and immunity. However, the extent to which such properties play a
significant role during infection in vivo has remained unclear. A murine model of acute P. aeruginosa lung infection was
utilised, demonstrating cathelicidin-mediated enhancement of bacterial clearance in vivo. The delivery of exogenous
synthetic human cathelicidin LL-37 was found to enhance a protective pro-inflammatory response to infection, effectively
promoting bacterial clearance from the lung in the absence of direct microbicidal activity, with an enhanced early
neutrophil response that required both infection and peptide exposure and was independent of native cathelicidin
production. Furthermore, although cathelicidin-deficient mice had an intact early cellular inflammatory response, later
phase neutrophil response to infection was absent in these animals, with significantly impaired clearance of P. aeruginosa.
These findings demonstrate the importance of the modulatory properties of cathelicidins in pulmonary infection in vivo and
highlight a key role for cathelicidins in the induction of protective pulmonary neutrophil responses, specific to the infectious
milieu. In additional to their physiological roles, CHDP have been proposed as future antimicrobial therapeutics. Elucidating
and utilising the modulatory properties of cathelicidins has the potential to inform the development of synthetic peptide
analogues and novel therapeutic approaches based on enhancing innate host defence against infection with or without
direct microbicidal targeting of pathogens.
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Introduction
Cationic host-defence peptides (CHDP; also known as antimi-
crobial peptides or AMPs) are important components of early
innate host defences. In addition to their physiological roles, these
peptides and their derivatives have been proposed as future
antimicrobial therapeutics, relatively unaffected by the develop-
ment of sustained microbial resistance [1]. Although initially
characterised as directly microbicidal agents, it is now clear that
many CHDP also have multiple functions as modulators of
inflammation and immunity [2,3,4], with emerging roles in
diseases affecting multiple organs including the lung, skin and
gastrointestinal tract. Human clinical trials using analogues of
CHDP modified to maximise direct microbicidal function have
achieved only moderate efficacy [5], perhaps due to failure to
recognise the importance of the immunomodulatory functions of
the native peptides. Interestingly, studies using non-microbicidal
analogues of naturally-occurring CHDP that retained other
bioactive functions, have demonstrated effective host defence
augmentation in mice [6,7]. These studies raise questions about
the relative roles of microbicidal and immunomodulatory prop-
erties of naturally-occurring CHDP in infections.
Cathelicidins are multipotent immunomodulatory CHDP [8].
The sole human cathelicidin Human Cationic Antimicrobial
Peptide of 18 kDa (hCAP-18; encoded by CAMP) is expressed by
multiple cell types including neutrophils, where it is stored in
specific granules and proteolytically cleaved following release, to
produce a 37 amino acid mature peptide fragment named LL-37
[9,10]. hCAP-18/LL-37 is upregulated in pulmonary infections
[11] and, in children with RSV bronchiolitis, low serum
cathelicidin is correlated with more severe disease [12]. Mice, like
humans, express only a single cathelicidin gene; Camp (encoding
the mCRAMP peptide) [13], with similar patterns of expression,
which is cleaved to produce an active 34 amino acid peptide [14].
Mice deficient in mCRAMP (Camp2/2) have increased suscep-
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tibility to bacterial infections of the skin [15], intestinal tract [16],
cornea [17] and urinary tract [18]. These Camp2/2 mice also
have impaired host defence against lung infection [19,20], while
therapeutic use of LL-37 and/or mCRAMP in wild type mice is
protective in models of pulmonary infection with P. aeruginosa [21]
or influenza virus [22]. These studies demonstrate a critical, non-
redundant role for endogenous cathelicidin in host defence against
lung infection and the therapeutic potential of the unmodified
peptides, but the mechanisms by which pulmonary host defence is
enhanced in vivo remains unclear. Although generally presented as
being primarily a consequence of direct microbicidal activity, this
is not fully consistent with in vivo concentrations and microbicidal
properties in a physiological environment. However, the extent to
which any of the plethora of immunomodulatory properties
ascribed to cathelicidins play a significant role during infection has
never been demonstrated in vivo. Understanding the critical
modulatory roles of native CHDP and how these contribute to
innate host defence against infection, may prove to be vital in
development of specific pathogen-targeted analogues of these
peptides for therapeutic use.
Respiratory diseases are among the most common causes of
morbidity and account for 1 in 5 deaths in the UK [23]. A third of
mortalities are due to acute respiratory infections, influenza or
pneumonia and pathogens resistant to conventional therapeutics
represent an increasing clinical challenge. Pseudomonas aeruginosa is
the primary cause of nosocomial pulmonary infections and
pulmonary colonisation with this pathogen is considered to be
responsible for the fatal deterioration of lung function in patients
with cystic fibrosis (CF) (reviewed in [24]). This opportunistic
pathogen is difficult to treat because of its widespread resistance to
multiple antibiotics [25], with the limited number of effective
antimicrobial treatments reduced further by the emergence of
carbapenem-and polymyxin-B resistant isolates [26]. A greater
understanding of the natural host defence mechanisms involved in
pulmonary defence against this organism is required in order to
develop novel therapeutic approaches. Cathelicidins can alter
susceptibility to pulmonary infection with P. aeruginosa in murine
models [19,20,21], despite this pathogen being resistant to the
directly microbicidal effects of these peptides in the presence of
physiologically relevant levels of cations in vitro [27,28,29]. Thus,
the in vivo roles of endogenous cathelicidin in host defence against
P. aeruginosa, the relative effects of microbicidal and modulatory
properties, and the consequences of therapeutic targeting of
cathelicidin expression or exogenous delivery of peptide remain
unknown.
We demonstrate that therapeutically administered synthetic LL-
37 peptide can enhance the clearance of P. aeruginosa from the
murine lung, in the absence of demonstrable direct microbicidal
effects, and can induce an upregulation of the early neutrophil
response to pathogen in the lungs that is dependent both upon the
presence of the peptide and the pathogen. We show that despite a
normal early neutrophil response, second phase pulmonary
neutrophil influx was deficient in Camp2/2 mice, with impaired
clearance of pulmonary P. aeruginosa. Delivery of LL-37 to these
cathelicidin-deficient mice enhanced the neutrophil response and
restore bacterial clearance, demonstrating proof of principle for
therapeutic use of LL-37 in cathelicidin deficiency. These studies
indicate that the protective effects of cathelicidins in P. aeruginosa
infection in vivo can result from modulatory effects in innate
immune responses, synergising with infectious stimuli to enhance a
protective neutrophil response.
Materials and Methods
Peptide
LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVP-
RTES; MW 4493.33) was either synthesised by N-(9-fluorenyl)
methoxycarbonyl chemistry at the Nucleic Acid/Protein Service
unit at the University of British Columbia (UBC; Vancouver,
Canada), or custom synthesised by Almac (East Lothian, Scotland)
using Fmoc solid phase synthesis and reversed phase HPLC
purification. Peptide identity was confirmed by electrospray mass
spectrometry, purity (.95% area) by RP-HPLC and net peptide
content determined by amino acid analysis. Lyophilised peptides
were reconstituted in endotoxin free water at 5 mg/ml stock
concentration and determined to be endotoxin-free using a
Limulus Amebocyte Lysate Chromogenic Endotoxin Quantitation
Kit (Thermo Scientific, UK). Peptide functionality was confirmed
by assessing anti-endotoxic activity [30].
Bacteria
Pseudomonas aeruginosa strain PAO1 was grown in Luria Bertani
(LB) broth at 37uC in an orbital shaker (250 rpm) overnight to
achieve a stationary-phase suspension. Bacterial cultures were then
diluted 1:10 in fresh LB broth and incubated at 37uC for 90 min
to reach logarithmic phase. Standardisation was performed by
dilution with LB broth to an optical density of 0.1 at 595 nm using
spectrophotometry (WPA UV 1101, Biotech Photometer), then
bacteria were centrifuged at 1,5006g for 15 min and resuspended
in PBS for use.
Murine infection model
Mouse experiments were performed in accordance with Home
Office UK project licence 60/4216, under the Animal (Scientific
Procedures) Act 1986. Wild type control mice were all C57Bl/6
strain, supplied by Charles River Laboratories, UK, and housed at
the University of Edinburgh for at least two weeks before use, or
were animals bred from those mice. Camp 2/2 mice [15] were
bred to congenicity on a C57Bl/6 strain background and were the
offspring of homozygous mutant matings raised in the same facility
at the University of Edinburgh. Both male and female mice were
used, between 8–12 weeks old, housed in individually ventilated
cages and randomly assigned to treatment groups (no significant
difference were found in end points between male and female
mice). Mice were weighed, given a general anaesthetic (isofluor-
ane) in a category 2 biosafety hood, then held vertically by
scruffing over the front of the thorax and inoculated by an
intranasal delivery up to a total of 50 ml volume. Mice were
inoculated with 36107 colony forming units (cfu) of PAO1 or the
same volume of PBS, and 10 mg LL-37 peptide in PBS or PBS
only control. PBS alone (carrier for both bacteria and peptide) was
used as a control (rather than scrambled peptide, which previous
pulmonary infection studies indicated had no effects ([22] and
unpublished data), in order that the wild type control infected
animals were appropriate controls both for the LL-37-treated
infected wild types and for the infected Camp2/2 animals (in
which no peptide was delivered). Mice were then returned to
cages, placed on a heat mat to maintain body temperature, and
monitored and scored for signs of infection every 2 hours, with
peak of illness occurring at 6–8 hours post infection, followed by
recovery with diminishing severity score. Mice were re-weighed
and culled at selected timepoints (0, 6 or 24 hours), culled by
pentobarbital injection and lungs and trachea exposed by
dissection. Lungs were lavaged in 1 ml sterile PBS via intramedic
polyethylene tubing (Sigma Aldrich, UK) inserted into the trachea,
and bronchoalveolar lavage fluid (BALF) stored on ice. Following
Cathelicidin Drive Neutrophils to Clear Infection In Vivo
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e99029
lavage, lungs were either homogenised in 2 ml sterile PBS for cfu
counts or were perfused by PBS injection into the heart, then
removed and frozen for RNA preparation.
CFU counts
BALF or homogenised lungs were serially diluted in PBS, plated
on Pseudomonas Isolation agar (Becton Dickinson Difco, Oxford,
UK), incubated overnight at 37uC and bacterial colonies counted
using a Stuart SC6 colony counter. Total colonies on the lowest
dilution plate countable were multiplied by the appropriate
dilution factors to determine the total CFU count of the lung
tissue or BALF sample.
Cytospins and counts
BALF was centrifuged at 2006g for 5 minutes, and supernatant
was removed for cytokine measurement. Pelleted cells were
resuspended and counted by NucleoCounter YC-100 (Chemo-
Metec, Allerød, Denmark) automated cell number counting.
100 ml of cell suspension was then loaded onto a glass slide using
a disposable sample funnel and cytocentrifuged at 106g for 3
minutes in a Shandon Cytospin 2 centrifuge. Slides were air dried
for 20 minutes, fixed in methanol for 20 minutes, stained with Diff
Quik (Fisher Scientific, Loughborough, UK), and mounted in
DPX Mountant (Fluka BioChemika/Sigma Aldrich, UK). Differ-
ential counts for neutrophils and monocytes were then performed
by light microscopy at 206 magnification using an EVOS FL
microscope (Peqlab, Sarisbury Green, UK).
ELISAs
BALF was used to measure cytokine levels by ELISA according
to manufacturer’s instructions, for KC, MIP-2 alpha (R&D
Systems, UK) or using a cytometric bead assay mouse inflamma-
tion kit (BD Biosciences, UK) for TNF, IL-6, MCP-1, IL-10, IFN-
gamma, IL-12p70.
qRT-PCR
Mouse lung tissue was homogenized in Qiagen RLT buffer
(Qiagen, Manchester, UK) using a Precellys 24 homogeniser with
Precellys-Keramik-kit ceramic beads (PeqLab). RNA was then
prepared from homogenised mouse lung tissue using RNeasy mini
kits (Qiagen), according to the manufacturer’s instructions. After
DNase treatment with RQ1 DNase (Promega, Southampton,
UK), cDNA was prepared from RNA using TaqMan reverse
transcriptase reagents and random hexamer primers (Life Tech-
nologies Ltd, Paisley, UK), according to the manufacturer’s
instructions. Quantitative Real Time PCR was performed on a
StepOne Real Time PCR machine (Life Technologies), using
Gene Expression Mastermix and TaqMan gene expression assays
for Camp (assay I.D. Mm00438285_m1) and 18S (assay I.D.
Mm03928990_g1). Relative quantitation of Camp was calculated
using the DCT method.
Analysis of mCRAMP protein expression
Harvested lung tissue was placed in 600 ml M-PER Mammalian
Protein Extraction Reagent with Complete Protease Inhibitor
Cocktail (Roche Applied Science, Burgess Hill, UK) added, and
homogenised using a Precellys 24 homogeniser with Precellys-
Keramik-kit ceramic beads (PeqLab). Homogenised tissue was
shaken on an IKA-Vibramax-VXR (Sigma Aldrich, UK)) for 20
minutes at 4uC and lysates were subsequently centrifuged at
15,0006g for 10 minutes at 4uC to pellet insoluble material.
Protein concentration in lysates was measured by Pierce BCA
assay (Thermo Scientific), according to manufacturer’s instruc-
tions. Lysate concentrations were equalised with lysis buffer, and
subsequently boiled at 96uC for 5 minutes in the presence of
loading buffer and reducing agent (Life Technologies), then run on
Novex NuPAGE 4–12% Bis-Tris pre-cast gels, in MOPS buffer
(Life Technologies), and subsequently transferred to Novex 0.2 mm
pore Nitrocellulose Membrane. mCRAMP was detected with
rabbit anti-mouse mCRAMP antibody (R-170, Santa Cruz
Biotechnology, Heidelberg, Germany), followed by staining with
IRDye 800CW anti-rabbit secondary antibody, with subsequent
detection using a LI-COR Odyssey Infrared Imaging System.
Rabbit pan-actin antibody (Cell Signalling Technology, Danvers,
MA, USA) staining was used as a loading control, detected with
anti-rabbit secondary antibody and infrared imaging as above.
Mouse CRAMP staining was then quantitated using LI-COR
Odyssey software.
Statistics
Statistical analyses were performed using Graphpad Prism
version 5.04 for Windows. Bacterial counts were normalised by
logarithmic transformation before analysis by 2 way ANOVA with
Bonferroni’s post tests where appropriate. Cell counts and cytokine
concentrations were analysed by Mann Whitney test. Differences
were considered statistically significant at P,0.05.
Results
LL-37-mediated microbicidal activity against
P. aeruginosa PAO1 is not observed in vivo
LL-37 and other CHDP were initially described as having rapid
direct microbicidal properties based on in vitro studies conducted
under favourable ionic environments (reviewed in [27]). However,
the activity of LL-37 can be inhibited by physiological levels of
divalent cations [27,28], serum apolipoprotein, f-actin and DNA
[31,32,33]. Thus, the relative contributions of microbicidal versus
modulatory properties in conferring the protective effects of this
peptide in vivo remain uncertain. We and others have shown that
LL-37 has negligible microbicidal activity against P. aeruginosa in
vitro [27,28,29]. In order to evaluate the contribution of any early
direct microbicidal properties of exogenously delivered LL-37
peptide in a murine pulmonary P. aeruginosa infection model, mice
were culled immediately after the intranasal delivery of bacteria
with peptide or carrier-only control to the cohort. Lungs were
removed, homogenised and plated to evaluate the number of
viable bacteria in the lungs. These samples are referred to as t = 0,
however homogenisation did not occur until 60 minutes after
inoculation, during which time interaction between peptide and
bacteria could occur. No significant difference was observed
between infected mice receiving LL-37 and control infected
animals (Fig 1a) demonstrating that LL-37, under these conditions,
had no discernable early microbicidal affects.
Therapeutic delivery of LL-37 is protective against
P. aeruginosa infection in vivo
In order to evaluate the protective antimicrobial properties of
LL-37 against P. aeruginosa PAO1 in vivo, mice were infected with or
without concomitant delivery of LL-37. All mice lost ,4% body
weight in the first 6 hours post procedure (data not shown), with
infected animals continuing to lose weight over 24 hours, but no
significant effect of LL-37 treatment was observed (Fig 1b). Mice
were culled 6 and 24 hours post-infection and the total number of
viable bacteria in the BALF (bronchoalveolar lavage fluid) and
lung homogenate was assessed (Fig 1 c–f). At 6 hours post-
infection, treatment with LL-37 showed no statistically significant
effect on the total number of bacteria in the lung homogenates, but
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did result in significantly lower levels of bacteria in the BALF
(Fig 1c/d). By 24 hours post-infection, LL-37 treatment had
significantly enhanced pathogen clearance from the lungs,
compared to controls, leaving only a residual infection,
inaccessible to BAL (Fig 1e/f). These data demonstrate the
capacity of LL-37 to enhance pulmonary bacterial clearance in the
absence of early microbicidal properties.
Figure 1. Exogenous LL-37 enhances pulmonary clearance of P. aeruginosa. Wild type C57Bl/6 mice were weighed, then inoculated with
36107 cfu of P. aeruginosa PAO1 or PBS and 10 mg LL-37 peptide or PBS by intranasal delivery. a) Immediately after inoculation of all mice, a subset
(called 0 hr; n = 3 per group) were culled and their lungs homogenised (60 minutes after initial inoculation), or b–f) 6 or 24 hours after inoculation
mice were re-weighed and culled, and their lungs were lavaged before homogenisation. BALF and lung homogenates were serially diluted, plated
and incubated overnight at 37uC before bacterial colonies were counted and corrected for volume. Mean PAO1 cfu +/2 SEM in the lung homogenate
(a, c & e) or BALF (d & f) for infected animals (n$9 per condition) are displayed. No bacteria were detected in samples from uninfected mice. b) Data
show mean percentage weight loss +/2 SEM. For statistical analyses bacterial counts were normalised by logarithmic transformation. Analyses were
conducted using 2 way ANOVA with Bonferroni’s post tests; * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0099029.g001
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Therapeutic delivery of LL-37 enhances neutrophil
responses in infected animals
Cathelicidins have been proposed to have multiple inflammo-
modulatory properties that could modulate the clearance of
infection in vivo [2], including direct chemotactic activity of LL-37
for neutrophils and monocytes [34,35,36,37,38]. Differential
cytospin cell counts were performed on the BALF from LL-37-
treated and control-treated infected and uninfected mice at 6 and
24 hours after infection. LL-37 treatment resulted in a significantly
upregulated neutrophil response to infection (over 2 fold increase
in median cell number) compared to control infected animals at
6 hours post-infection (Fig 2a). No neutrophils were detected in
the BALF from uninfected mice, regardless of LL-37 treatment, at
this timepoint (Fig 2b). Whereas a larger second phase neutrophil
response was observed by 24 hours in control-treated infected
mice, the mean neutrophil number in the LL-37-treated infected
animals was actually significantly lower than the controls at this
timepoint, in line with the enhanced earlier clearance of the
infection (Fig 2c). A degree of neutrophil influx was observed in
response to LL-37 alone at 24 hours in uninfected mice (Fig 2d).
In contrast, no significant LL-37-mediated effects on pulmonary
monocyte numbers were observed at 6 or 24 hours in infected
(Fig 2 e/f) or uninfected (data not shown) mice.
Therapeutic delivery of LL-37 does not affect pulmonary
cytokine responses in infected animals
In order to determine whether LL-37-mediated enhanced
neutrophil responses were secondary to modulation of pulmonary
cytokine and chemokine responses, CBA (Cytometric Bead Array)
and ELISA assays were performed on the BALF from LL-37-
treated and control-treated infected mice at 6 and 24 hours after
infection, to determine the concentrations of TNF, IL-6, MIP-2,
KC, MCP-1, IL-10, IFNc and IL-12. Although TNF, IL-6, MIP-
2, KC and MCP-1 were all highly expressed in response to
infection at 6 hours (Fig 3a–e) compared to baseline levels in
uninfected mice (data not shown), and resolving by 24 hours
(Fig 3f–j), treatment with LL-37 had no significant effect on any of
the cytokines measured. In contrast, IL-10, IFNc and IL-12 were
not detected in significant quantities.
Pulmonary infection with P. aeruginosa induces Camp
expression in the murine lung
In this model, therapeutic administration of LL-37 was in
addition to any effects of endogenous murine cathelicidin
mCRAMP produced in the murine lungs in response to infection.
mCRAMP has also been shown to have neutrophil chemotactic
properties in vivo, in an air pouch model [36]. Thus, in order to
establish the temporal expression pattern of Camp in P. aeruginosa
infected mice, qRT-PCR and western immunoblot analyses were
performed on lung homogenates at 0, 2, 6 and 24 hours post-
infection. Camp transcription was not detected at 0 hour, but was
detectable at very low levels by 2 hours after infection. Transcrip-
tion was dramatically increased at 6 and 24 hours after infection
(upregulated 1886-fold, +/2137, and 1124-fold, +/266 respec-
tively, relative to the 2 hour timepoint), with mCRAMP protein
clearly detectable at these timepoints (data not shown) in keeping
with previously published data [20]. Thus, the inflammatory
responses were potentially modified by cathelicidin from around
6 hours post-infection in all mice, but additionally modified by
cathelicidin within the first few hours in mice receiving an
intranasal bolus of LL-37.
Endogenous mCRAMP is protective against P. aeruginosa
infection in vivo
In order to evaluate the protective antimicrobial properties of
induced endogenous mCRAMP against P. aeruginosa PAO1 in this
model, Camp 2/2 mice were infected and compared to wild type
control animals. The profile of weight loss in infected Camp 2/2
mice was not significantly different from the wild type control (data
not shown). Mice were culled 6 and 24 hours post-infection and
the total number of viable bacteria in the BALF and lung
homogenate was assessed (Fig 4 a–d). At 6 hours post-infection
Camp 2/2 mice showed no statistically significant difference in
the total number of bacteria in the lung homogenates or BALF
when compared to infected wild type controls (Fig 4 a/b).
However, by 24 hours post-infection, wild type mice had more
effectively cleared the bacteria, with significantly higher pathogen
loads found in both the lung homogenates and BALF from the
Camp 2/2 mice (Fig 4c/d). These data demonstrate the capacity
of endogenous mCRAMP to enhance pulmonary bacterial
clearance, occurring after inducible Camp expression is detectable
in the lungs of wild-type mice.
Endogenous mCRAMP enhances neutrophil responses in
infected animals
The extent to which endogenous mCRAMP might play a role
in the pulmonary neutrophil response to P. aeruginosa infection was
examined by comparing BALF cytospin differential cell counts
from infected Camp 2/2 mice and wild type mice at 6 and
24 hours after infection. No significant differences were observed
in neutrophil or monocyte counts at 6 hours (Fig 5a/b), with an
initial neutrophil influx occurring similarly in both genotypes
(Fig 5a). However, Camp 2/2 mice failed to further upregulate
this response, demonstrating a significantly less elevated neutrophil
count than wild type controls at 24 hours (Fig 5c). A trend towards
fewer monocytes was also observed, but did not reach significance
(Fig 5d). These data indicate that endogenous mCRAMP is not
involved in the first phase of neutrophil influx, but is required,
following induction, for the second phase neutrophil response to P.
aeruginosa infection. TNF, IL-6, MIP-2, KC and MCP-1 were all
highly expressed in response to infection in Camp 2/2 mice at
6 hours (Fig 6a–e), and resolving by 24 hours (Fig 6f–j), but were
not significantly different from the responses quantified in infected
wild type mice.
Therapeutic delivery of LL-37 can restore protection
against P. aeruginosa infection in cathelicidin deficient
mice
Cathelicidin insufficiency has been associated with increased
susceptibility to infection in humans [12,39,40]. Thus, in order to
determine whether therapeutic use of synthetic human LL-37
could restore cathelicidin-mediated protective antimicrobial func-
tion in cathelicidin deficiency, Camp 2/2 mice were infected with
P. aeruginosa PAO1 in vivo, with or without concomitant delivery of
LL-37. The profile of weight loss in infected Camp 2/2 mice was
not significantly altered by delivery of LL-37 (data not shown).
Mice were culled 6 and 24 hours post-infection and the total
number of viable bacteria in the BALF (bronchoalveolar lavage
fluid) and lung homogenate was assessed (Fig 7 a–d). At 6 hours
post-infection, treatment with LL-37 showed no significant effect
on the total number of bacteria in the lung homogenates (despite a
trend towards enhanced clearance), but led to significantly lower
levels of bacteria in the BALF (Fig 7a/b). By 24 hours post-
infection, LL-37 treatment had very significantly enhanced
pathogen clearance from the lungs, compared to control-treated
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Camp 2/2 (Fig 7c/d). These data demonstrate that delivery of
exogenous synthetic LL-37 can enhance host defence against
infection by mechanisms that do not require endogenous host
cathelicidin production, and show cross-species functionality of
these peptides.
Therapeutic delivery of LL-37 promotes an early
neutrophil response to P. aeruginosa infection,
associated with enhanced clearance
Cathelicidin-mediated enhancement of bacterial clearance was
associated with upregulated neutrophil influx in LL-37-treated
infected wild type mice (compared to untreated infected controls).
However, in addition, endogenous cathelicidin clearly also had a
critical role in the induction of a maximal neutrophil responses to
infection. Thus, in order to determine whether LL-37-mediated
enhanced neutrophil responses were independent of endogenous
cathelicidin production, BALF cytospin differential cell counts
were also evaluated from LL-37-treated and control infected Camp
2/2 mice at 6 and 24 hours after infection. As also observed in
LL-37-treated wild type mice (Fig 2a), early, infection-induced
neutrophil influx (at 6 hours) was significantly greater in LL-37-
treated mice (Fig 8a), but this early effect of the therapeutic bolus
was lost by 24 hours (Fig. 8b). However, whereas wild type mice
showed a robust later neutrophil response to infection regardless of
peptide treatment (Fig 2c), this second phase neutrophil response
failed to occur in infected Camp 2/2 mice, irrespective of peptide
treatment (Fig 8b), demonstrating the dependence of this later
response upon pathogen-induced Camp expression. No significant
Figure 2. Exogenous LL-37 promotes an early neutrophil response to P. aeruginosa. Wild type C57Bl/6 mice were inoculated with
36107 cfu of P. aeruginosa PAO1 or PBS and 10 mg LL-37 peptide or PBS by intranasal delivery. At 6 hours (a, b & e) or 24 hours (c, d & f) after
inoculation mice were culled and their lungs were lavaged. BALF was cytocentrifuged and differential counts were conducted for neutrophils (a–d)
and monocytes (e & f). Data show Tukey box and whiskers plots for infected (a, c, e & f) (n$9 per condition) and uninfected (b & d) animals (n$5 per
condition). Analyses were conducted using the Mann Whitney test; * p,0.05. ND denotes ‘‘not detected’’.
doi:10.1371/journal.pone.0099029.g002
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Figure 3. P. aeruginosa, but not exogenous LL-37, induces pulmonary cytokine responses. Wild type C57Bl/6 mice were inoculated with
36107 cfu of P. aeruginosa PAO1 and 10 mg LL-37 peptide or PBS by intranasal delivery. At 6 hours (a–e) or 24 hours (b–j) after inoculation, mice were
culled and their lungs were lavaged. BALF was centrifuged to remove cells and levels of TNF (a, f), IL-6 (b, g), MIP-2 (c, h), KC (d, i) and MCP-1 (e, j) were
determined. Data show Tukey box and whiskers plots for n$9 animals per condition. Analyses were conducted using the Mann Whitney test.
doi:10.1371/journal.pone.0099029.g003
Figure 4. Cathelicidin-deficient mice display impaired pulmonary clearance of P. aeruginosa. Camp2/2mice and wild type controls were
inoculated with 36107 cfu of P. aeruginosa PAO1 or PBS by intranasal delivery. At 6 or 24 hours after inoculation mice were culled and their lungs
were lavaged before homogenisation. BALF and lung homogenates were serially diluted, plated and incubated overnight at 37uC before bacterial
colonies were counted and corrected for volume. Mean PAO1 cfu +/2 SEM in the lung homogenate (a & c) or BALF (b & d) for infected animals (n$10
per condition) are displayed. No bacteria were detected in samples from uninfected mice. For statistical analyses bacterial counts were normalised by
logarithmic transformation. Analyses were conducted using 2 way ANOVA with Bonferroni’s post tests; * p,0.05.
doi:10.1371/journal.pone.0099029.g004
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effects upon monocyte counts were observed (data not shown).
These data demonstrate that the early infection-mediated neutro-
phil response, enhanced by the bolus of LL-37, was independent of
endogenous cathelicidin expression and associated with enhanced
clearance of pulmonary P. aeruginosa.
Figure 5. Cathelicidin-deficient mice display impaired late neutrophil responses to P. aeruginosa. Camp2/2 mice and wild type controls
were inoculated with 36107 cfu of P. aeruginosa PAO1 by intranasal delivery. At 6 hours (a & b) or 24 hours (c & d) after inoculation mice were culled
and their lungs were lavaged. BALF was cytocentrifuged and differential counts were conducted for neutrophils (a & c) and monocytes (b & d). Data
show Tukey box and whiskers plots for n$8 animals per condition. Analyses were conducted using the Mann Whitney test; * p,0.05.
doi:10.1371/journal.pone.0099029.g005
Figure 6. P. aeruginosa, but not cathelicidin sufficiency, induces pulmonary cytokine responses. Camp2/2 mice and wild type controls
were inoculated with 36107 cfu of P. aeruginosa PAO1 by intranasal delivery. At 6 hours (a–e) or 24 hours (b–j) after inoculation, mice were culled
and their lungs were lavaged. BALF was centrifuged to remove cells and levels of TNF (a, f), IL-6 (b, g), MIP-2 (c, h), KC (d, i) and MCP-1 (e, j) were
determined. Data show Tukey box and whiskers plots for n$8 animals per condition. Analyses were conducted using the Mann Whitney test.
doi:10.1371/journal.pone.0099029.g006
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Discussion
Cathelicidins are recognised as key multifunctional modulators
of innate immunity and host defence against infection, and offer
possible novel therapeutic templates. In addition to directly
microbicidal potential, these peptides have been described as
having a broad range of inflammomodulatory and immunomod-
ulatory properties [2]. However, no clear evidence exists for these
functions being involved in cathelicidin-mediated enhanced host
defence against pulmonary infection in vivo, with the relative
significance of microbicidal potential and modulatory functions
remaining unclear. Using a murine model of acute P. aeruginosa
lung infection, we demonstrate cathelicidin-mediated enhance-
ment of bacterial clearance in vivo in the absence of direct early
Figure 7. Exogenous LL-37 enhances pulmonary clearance of P. aeruginosa in cathelicidin-deficient mice. Camp2/2 mice were
inoculated with 36107 cfu of P. aeruginosa PAO1 or PBS and 10 mg LL-37 peptide or PBS by intranasal delivery. At 6 or 24 hours after inoculation mice
were re-weighed and culled, and their lungs were lavaged before homogenisation. BALF and lung homogenates were serially diluted, plated and
incubated overnight at 37uC before bacterial colonies were counted and corrected for volume. Mean PAO1 cfu +/2 SEM in the lung homogenate (a &
c) or BALF (b & d) for infected animals (n$6 per condition at 6 hours and n$10 per condition at 24 hours) are displayed. No bacteria were detected in
samples from uninfected mice. For statistical analyses bacterial counts were normalised by logarithmic transformation. Analyses were conducted
using 2 way ANOVA with Bonferroni’s post tests; ** p,0.01, *** p,0.001.
doi:10.1371/journal.pone.0099029.g007
Figure 8. Exogenous LL-37 promotes an early neutrophil response to P. aeruginosa in cathelicidin-deficient mice. Camp2/2mice were
inoculated with 36107 cfu of P. aeruginosa PAO1 and 10 mg LL-37 peptide or PBS by intranasal delivery. At 6 hours (a) or 24 hours (b) after
inoculation mice were culled and their lungs were lavaged. BALF was cytocentrifuged and differential counts were conducted for neutrophils. Data
show Tukey box and whiskers plots for n$8 animals per condition. Analyses were conducted using the Mann Whitney test; * p,0.05.
doi:10.1371/journal.pone.0099029.g008
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microbicidal activity. Administration of synthetic LL-37 promoted
an upregulation of the early neutrophil response that was
dependent upon both infection and peptide, but was independent
of native cathelicidin production, and enhanced bacterial clear-
ance from the lung. Mice deficient in endogenous mCRAMP had
a normal initial neutrophil response to infection, during a period in
which Camp was not initially expressed in the wild type lung.
However, these Camp2/2 mice were deficient in the larger
second phase neutrophil response observed in Camp-expressing
infected wild type mice and had an impaired capacity to clear the
infection. To our knowledge, this is the first demonstration of
cathelicidins enhancing host defence against infection through
primarily modulatory mechanisms in vivo and suggests induction of
a cathelicidin-mediated protective proinflammatory response.
The associations between hCAP-18/LL-37 expression and
susceptibility to infection in humans [39][40][11][12] suggest an
important, but as yet undefined role for hCAP-18/LL-37 in innate
host defence against infection in humans. Although this peptide
has microbicidal potential, its activity is poor against many
microorganisms in physiologically relevant environments at the
low concentrations found in vivo in most systems [27,28,29].
However, cathelicidins have additionally been shown to have
multiple modulatory activities, including chemotactic function
[34,35,36,37,38], the ability to modulate chemokine, cytokine and
cellular responses [30,41,42,43], the capacity to alter leukocyte
differentiation and function [44,45,46] and cell death modulating
properties [28,47,48]. Critical to understanding these peptides and
utilising their properties therapeutically is the need to clarify their
modes of action in vivo in infectious contexts.
In this study, an acute murine pulmonary infection model with
P. aeruginosa was utilised in order to evaluate the capacity of
cathelicidins to enhance host defence against infection with a
microbe which is largely resistant to these peptides under
physiological conditions in vitro [27,28,29]. Under favourable in
vitro conditions in which microbicidal properties are evident for
LL-37, this peptide has been shown to permeabilise bacterial
membranes within minutes [49]. However, we found no evidence
for direct microbicidal activity against P. aeruginosa after co-
incubation with LL-37 in vivo, yet exogenously delivered LL-37 was
found to significantly enhance pathogen clearance over 24 hours.
Although we cannot exclude some alternative form of late direct
microbicidal activity of LL-37, even by 6 hours after infection no
significant impact on bacterial load of the whole lung could be
demonstrated in response to LL-37 treatment, although interest-
ingly a therapeutic bolus of peptide was found to diminish the
number of live bacteria accessible to bronchoalveolar lavage at this
time point. The reason for this is unclear, but may relate to early
removal of the most accessible bacteria by the enhanced
neutrophil influx observed. A previous study using adenoviral
vectors carrying the cDNA for hCAP18/LL-37, to overexpress the
human cathelicidin in the murine lung over the 5 days prior to
infection, resulted in the promotion of a small, but significant
enhancement of P. aeruginosa clearance from the murine lung over
a 24 hour period [21]. This was observed to be accompanied by
decreased pulmonary TNF levels, but the mechanism underpin-
ning this therapeutic effect was not evaluated and was assumed to
be microbicidal. In contrast, we found no evidence to support a
microbicidal effect, but demonstrate a peptide-mediated enhanced
early neutrophil influx in vivo.
Prior research has demonstrated the capacity for cathelicidins to
have direct chemotactic activity for human neutrophils and
monocytes and murine leukocytes in vitro [34,36] and for murine
leukocytes in an experimentally-formed murine air pouch model
[36]. In that in vivo model, injection of 2 mM LL-37 or mCRAMP
into the air pouch significantly enhanced the influx of neutrophils
and monocytes within a 4 hour period. This is in contrast to the
complete absence of neutrophils observed in our studies in the
murine lung 6 hours after instillation of LL-37 alone (Figure 2b).
In addition, LL-37 was not found to mediate any significant effects
on the number of monocytes in the BALF, in contrast to the
previously published findings in other systems [35,36]. A small, but
significant neutrophil response was observed in the lungs of LL-37-
treated uninfected mice at 24 hours after instillation (Figure 2d),
demonstrating some LL-37-mediated neutrophil influx. However,
indirect effects cannot be excluded and LL-37 has also been shown
to enhance the production of neutrophil chemokines by other cells
[30,50]. Nevertheless, despite this absence of any substantial
response to LL-37 alone, a significantly enhanced pulmonary
neutrophilia was observed in response to LL-37 upon concomitant
infection (Figure 2a). With regard to this apparent contradiction to
previous findings, it is worth noting that even the control air
pouches in the previous report yielded a substantial number of
neutrophils [36], indicating that this was already an inflamed
environment and may in fact be analogous to infected lungs in our
study. The requirement for concomitant infection in order to
establish the early enhanced LL-37-mediated neutrophil response
suggests a synergy with inflammatory mediators that remain to be
identified, with no peptide-mediated modulation having been
observed in the levels of the chemokines studied (including KC,
MIP2, MCP-1, TNF and IL-6). Nevertheless, these data provide
clear evidence for the in vivo capacity of exogenous LL-37 to
modulate the innate cellular immune response in the context of
pulmonary infection, enhancing pathogen clearance in the
absence of microbicidal activity and having potential therapeutic
implications.
In addition to the potential therapeutic roles of exogenous
cathelicidins, the primary roles of endogenous peptides in
pulmonary infection remain unclear. Studies using Camp2/2
mice have demonstrated a deficiency in the clearance of both
pulmonary Klebsiella pneumoniae and P. aeruginosa infections [19,20].
K. pneumoniae promoted a later induction of pulmonary Camp
expression than P. aeruginosa and mCRAMP appeared to have a
more potent effect on K. pneumoniae, with Camp2/2 mice having a
significant and severe clearance defect at 24 hours, resulting in
more florid inflammation by 48 hours in the absence of
endogenous cathelicidin and increased mortality [20]. Given that,
in the case of K. pneumoniae, mCRAMP was reported to have
microbicidal effects at a relatively modest 1 mM, it is possible that
the phenotype in this particular infection was influenced by loss of
a relevant microbicidal agent in the face of a lethal infectious dose.
Indeed, the late induction of Camp in wild type mice infected with
K. pneumoniae may suggest less relevance for the peptide in the
inflammatory response to this particular infection. In contrast, we
demonstrate that P. aeruginosa infection can ultimately be
controlled and cleared even in the absence of mCRAMP, and
the earlier expression in wild type mice may indicate a more
important role in the inflammatory response. The previous study
reported that Camp2/2 mice infected with P. aeruginosa (at a lower
infectious dose than in our study) has a significantly impaired
bacterial clearance at 48 hours, with a decreased neutrophil
response at 24 hrs [20]. These observations are compatible with
our study, but were attributed to a loss of a direct chemotactic
response to endogenous cathelicidin. Our new data, examining
earlier timepoints, indicate that the initial murine pulmonary
neutrophil response to P. aeruginosa infection precedes induction of
and is independent of mCRAMP, and thus proceeded normally in
Camp2/2 mice. However, second phase neutrophil influx was
dependent upon mCRAMP expression, which may synergise with
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infection-induced factors as yet unidentified, and was therefore
defective in Camp2/2 mice, in whom impaired pathogen
clearance then occurred. These data suggest that in individuals
with impaired endogenous cathelicidin production, an effective,
protective pulmonary inflammatory response will be suboptimal.
hCAP-18/LL-37 in humans is pre-formed in neutrophil
granules, but can also be induced in a vitamin-D dependent
manner in epithelial cells and macrophages [51,52,53,54]. In
addition, strategies to induce LL-37 expression are under
development, including the use of compounds such as 4-
phenylbutyrate (reviewed in [55]), which can effectively upregulate
hCAP-18/LL-37 expression in vitro, including in airway epithelial
cells [56], and in vivo in a model of Shigella infection [57]. Such
approaches may be of value in enhancing protective cathelicidin
expression in humans, particularly in vitamin-D insufficient
seasonal conditions. However, it was also important to consider
whether therapeutic application of cathelicidin could provide
rapid short term improvement of host defence in the absence of
effective endogenous cathelicidin expression. In this regard, our
studies demonstrate that the delivery of LL-37 to P. aeruginosa
infected mice could promote an early neutrophil response and
enhanced pathogen clearance in Camp2/2 mice as effectively as
in wild type mice. These data indicate that this protective effect
was in response to the exogenous LL-37 delivered, independent of
endogenous mCRAMP expression and of native cathelicidin
release from incoming PMN and supports the potential for the use
of exogenous peptides in infection.
Thus, using a murine model of acute P. aeruginosa lung infection,
we demonstrate cathelicidin-mediated enhancement of bacterial
clearance in vivo in the absence of direct microbicidal activity. The
delivery of exogenous cathelicidin functioned to enhance a
protective pro-inflammatory response to infection, promoting
bacterial clearance from the lung, with an infection- and peptide-
dependent early neutrophil response that was independent of
native cathelicidin production. Furthermore, although Camp2/2
mice had an intact early cellular inflammatory response (which
was comparable to cathelicidin-sufficient animals in the period
preceding the induction of mCRAMP expression), they had
significantly impaired bacterial clearance and absence of a second
phase neutrophil response to infection. These finding demonstrate
the importance of the inflammomodulatory properties of cathe-
licidins in pulmonary infection in vivo and highlight the significance
of understanding and utilising these properties in the development
of novel therapeutic approaches.
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